Enjoy complimentary customisation on priority with our Enterprise License!
The global amyloidosis therapeutics market size will grow by USD 357.22 million during 2019-2023. This market report provides a detailed analysis of the market by type (systemic amyloidosis and other amyloidosis) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on many market vendors, including AbbVie Inc., Allergan Plc, Alnylam Pharmaceuticals Inc., Amgen Inc., Celgene Corp., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Johnson & Johnson Services Inc., Pfizer Inc., and Takeda Pharmaceutical Co. Ltd.
Key Insights on Amyloidosis Therapeutics Market - Global Forecast 2019-2023
Browse TOC and LoE with selected illustrations and example pages of on amyloidosis therapeutics market
Amyloidosis is a rare disease, and the amyloidosis therapeutics market has only three approved drugs. As a result, there is a significant unmet need for treatment providing potential business opportunities to vendors. Moreover, as the prevalence of the condition increases with age, the rising geriatric population is augmenting the need for effective therapeutics. Considering these factors, the market has been recording extensive R&D of novel therapies. Many organizations, such as Vasculitis Foundation and National Organization for Rare Disorders, have been providing research funding to small or mid-sized companies to complete their clinical trials and launch drugs.
The three approved drugs available in the amyloidosis market and the therapeutic candidates (under development) have been awarded special drug designations by regulatory bodies such as the US FDA and EMA. The designations include breakthrough drug designation and orphan drug designation. The sponsors of these drugs receive various incentives and tax benefits, encouraging vendors to expedite R&D on new molecules. This will support amyloidosis treatment market growth during the forecast period. As a result of these factors, the market will register a CAGR of almost 8% during 2019-2023.
The global market is fragmented. To help clients improve their market positions, this amyloidosis therapeutics market forecast report provides an analysis of the market’s competitive landscape and offers information on the drugs offered by various companies. The report also includes information on the upcoming amyloidosis treatment trends and challenges that will influence market growth. This will help companies in creating strategies to make the most of future growth opportunities.
The report offers a detailed analysis of several leading amyloidosis drugs manufacturers, including:
The systemic amyloidosis segment held the largest market share in 2018. The high prevalence of the condition, recent drug approvals, and growing geriatric population will boost the growth of the systemic amyloidosis market segment during the forthcoming years. This report provides an accurate prediction of the contribution of all the segments to the growth of the amyloidosis therapeutics market size.
With a complete study of the growth opportunities for companies, it has been identified that North America will account for the highest amyloidosis therapeutics market share throughout the forecast period. The sales of off-label drugs, increasing prevalence of subtypes of amyloidosis, and growing geriatric population are contributing to the amyloidosis therapeutics industry growth in the region.
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: MARKET LANDSCAPE
PART 04: MARKET SIZING
PART 05: FIVE FORCES ANALYSIS
PART 06: MARKET SEGMENTATION BY TYPE
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
PART 09: DRIVERS AND CHALLENGES
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
PART 12: VENDOR ANALYSIS
PART 13: APPENDIX
PART 14: EXPLORE TECHNAVIO
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.